论文信息 - The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial - 字舞流文

The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial

C. Buske | A. Ho | M. Dreyling | G. Hess | M. Witzens‐Harig | P. La Rosée | R. Marks | A. Viardot | U. Keller | J. Meissner | J. Atta | J. Wosniok | O. Deuster | J. Klemmer | A. Geueke | Oliver Deuster